Upgrade
|
Canaccord analyst Matt… Canaccord analyst Matt Bottomley upgraded Cronos Group to Hold from Sell with a price target of C$4.50, up from C$4.25. The company's Q1 results came in higher than expectations on continued gross margin expansion after finally inflecting into positive territory to end 2021, Bottomley tells investors in a research note. As of yesterday's closing price, Cronos Group's cash and short-term investments represented 93% of the company's C$1.4B market capitalization, says the analyst. Bottomley cites incremental operational improvements and a significant portion of the stock's current implied value supported by cash reserves for the upgrade. ShowHide Related Items >><< - 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/11/22 CIBC
- Cronos Group upgraded to Outperformer from Neutral at CIBC
- 05/11/22 Canaccord
- Cronos Group upgraded to Hold from Sell at Canaccord
- 05/09/22 Raymond James
- Cronos Group price target raised to $6 from $5 at Raymond James
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 11/15/21
- Republicans introduce cannabis legalization bill, Insider says
- 05/10/22
- What You Missed On Wall Street On Tuesday
- 05/10/22
- What You Missed On Wall Street This Morning
- 05/05/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 04/28/22
- Here's What You Missed in Cannabis This Week
- 03/25/22
- Unusually active option classes on open March 25th
- 11/12/21
- Cronos Group call volume above normal and directionally bullish
|
Upgrade
|
CIBC analyst John Zamparo… CIBC analyst John Zamparo upgraded Cronos Group to Outperformer from Neutral. ShowHide Related Items >><< - 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/11/22 Canaccord
- Cronos Group upgraded to Hold from Sell at Canaccord
- 05/09/22 Raymond James
- Cronos Group price target raised to $6 from $5 at Raymond James
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 03/22/22 Barclays
- Cronos Group upgraded to Equal Weight from Underweight at Barclays
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 11/15/21
- Republicans introduce cannabis legalization bill, Insider says
- 05/10/22
- What You Missed On Wall Street On Tuesday
- 05/10/22
- What You Missed On Wall Street This Morning
- 05/05/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 04/28/22
- Here's What You Missed in Cannabis This Week
- 03/25/22
- Unusually active option classes on open March 25th
- 11/12/21
- Cronos Group call volume above normal and directionally bullish
|
Upgrade
|
Canaccord analyst Matt… Canaccord analyst Matt Bottomley upgraded Cronos Group to Hold from Sell with a C$4.50 price target. ShowHide Related Items >><< - 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/09/22 Raymond James
- Cronos Group price target raised to $6 from $5 at Raymond James
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 03/22/22 Barclays
- Cronos Group upgraded to Equal Weight from Underweight at Barclays
- 03/21/22 Stifel
- Stifel takes neutral overall view of Cronos' CEO transition
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 04/11/22
- NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says
- 04/01/22
- U.S. House backs federal marijuana legalization bill, Marijuana Moment reports
- 03/24/22
- House to vote on marijuana legalization bill next week, Marijuana Moment says
- 11/15/21
- Republicans introduce cannabis legalization bill, Insider says
- 05/10/22
- What You Missed On Wall Street On Tuesday
- 05/10/22
- What You Missed On Wall Street This Morning
- 05/05/22
- Here's What You Missed in Cannabis, Psychedelics This Week
- 04/28/22
- Here's What You Missed in Cannabis This Week
- 03/25/22
- Unusually active option classes on open March 25th
- 11/12/21
- Cronos Group call volume above normal and directionally bullish
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 05/10/22
- UWM Holdings sees Q2 production in $26B-$33B range
- 03/01/22
- UWM Holdings sees Q1 production $33B-$42B
- 11/19/21
- UWM Holdings rises 18.4%
- 11/19/21
- UWM Holdings rises 24.3%
- $33.63 /
-43.55 (-56.43%) - 05/10/22
- Upstart Holdings trading resumes
- 05/10/22
- Upstart Holdings trading halted, volatility trading pause
- 05/09/22
- Upstart drops 44% to $43.30 after cutting FY22 guidance
- 04/25/22
- CFPB invokes dormant authority to examine nonbank companies
- $800.05 /
+12.745 (+1.62%) - 05/09/22
- Hindenburg shorts Twitter on risk of deal getting repriced lower
- 05/08/22
- Fly Intel: Top five weekend stock stories
- 05/06/22
- Elon Musk says hasn't had communication with Trump
- 05/06/22
- Vale confirms supply deal with Tesla for low-carbon nickel
- 05/10/22
- Teva publishes 2021 ESG Progess Report
- 05/03/22
- Teva says no major M&A planned for 'next several years'
- 05/03/22
- Teva says debt reduction continues as 'primary focus'
- 05/03/22
- Teva says biosimilar pipeline 'progressing nicely'
- 05/10/22
- SoFi Technologies off lows after resumption, remains down 13%
- 05/10/22
- SoFi Technologies trading resumes
- 05/10/22
- SoFi Technologies to resume trading at 2:10 pm ET
- 05/10/22
- SoFi Technologies CEO says 'off to a great start' standing up bank
- 05/10/22
- Peloton CEO: William Lynch to resign from board to pursue other interests
- 05/10/22
- Peloton: Recent price increases 'look promising'
- 05/10/22
- Peloton sees talent additions across organization in coming months, says CEO
- 05/10/22
- Peloton CEO: Price increase geared towards moving hardware
- 05/09/22
- Palantir falls -20.8%
- 05/09/22
- Palantir falls -21.7%
- 05/09/22
- Palantir falls -19.3%
- 04/15/22
- Palantir announces expansion to partnership with CDC
- 05/10/22
- Planet Fitness announces development agreement in New Zealand
- 01/12/22
- Planet Fitness says ended FY21 with 15.2M members
- 01/11/22
- Planet Fitness to acquire 114 locations from top franchisee, Sunshine Fitness
- 05/10/22
- Duke Realty jumps 18% to $56.53 after Prologis buyout proposal
- 05/10/22
- Prologis proposes to acquire Duke Realty in all-stock deal valued at $61.68
- 04/19/22
- Prologis CEO: We operate in 19 different countries
- 04/19/22
- Prologis reports Q1 Cash Same Store NOI 8.7%
- 05/10/22
- Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share
- 05/10/22
- Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash
- 05/06/22
- Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis
- 05/03/22
- Pfizer CEO says 'delivering on our production commitments for Paxlovid'
- $52.35 /
-13.58 (-20.60%) - 05/10/22
- Pegasystems trading resumes
- 05/10/22
- Pegasystems trading halted, volatility trading pause
- 02/17/22
- Pegasystems' President of Global Client Engagement to resign
- $177.65 /
+4.655 (+2.69%) - 04/20/22
- Pershing Square sells Netflix investment
- 04/19/22
- Netflix says will figure out advertising in next year or two
- 04/19/22
- Netflix says Q2 typically a softer quarter seasonally
- 04/19/22
- Netflix to test ways to charge for account sharing this year
- 05/03/22
- Match Group says Shar to step down as CEO, Bernard Kim to succeed
- 05/03/22
- Match Group names Bernard Kim as CEO
- 04/04/22
- Verizon's Visible, Match Group announce partnership on Singles Registry
- 04/28/22
- FDA proposes rules prohibiting menthol cigarettes and flavored cigars
- 04/13/22
- JUUL to pay Washington $22.5M over advertising practices
- 04/11/22
- Lexaria Bioscience enters new agreements with Altria Client Services
- 03/11/22
- FDA authorizes reduced exposure claim for IQOS 3 System Holder and Charger
- $2,292.38 /
+31.09 (+1.37%) - 05/09/22
- Match Group files lawsuit against Google over unlawful billing mandates
- 05/06/22
- Netlist says court grants motion for summary judgement in Google case
- 05/05/22
- Google acquires MicroLED display maker Raxium
- 05/04/22
- Google Cloud and SAP launch native integration between Workspace and S/4HANA C
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- 04/27/22
- Evofem enters agreement with GoodRx's VitaCare Prescription Services
- 05/10/22
- National Vision Holdings trading resumes
- 05/10/22
- National Vision Holdings trading halted, volatility trading pause
- 04/11/22
- National Vision appoints Joe VanDette as CMO
- 04/11/22
- National Vision announces Joe VanDette as chief marketing officer
- 05/10/22
- Duke Realty rises 15.3%
- 05/10/22
- Desktop Metal announces proposed convertible senior notes offering
- 05/09/22
- Desktop Metal 'supports' Biden Adminstration's AM Forward initiative
- 05/06/22
- Biden Administration announces launch of 'Additive Manufacturing Forward' plan
- 03/08/22
- Desktop Metal rises 11.3%
- 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/09/22
- Citi says regulators investigating CGMI over record-keeping compliance
- 05/09/22
- Citi in talks with 'number of potential buyers' for Russia operations
- 05/04/22
- Citi raises base rate to 4.00% from 3.50%
- 04/26/22
- Citi implementing U.S. sanctions against Russia, says CEO Fraser
BHVN Biohaven Pharmaceutical - $140.00 /
+56.78 (+68.23%) - 05/10/22
- Biohaven Pharmaceutical rises 70.2%
- 05/10/22
- Biohaven Pharmaceutical rises 70.8%
- 05/10/22
- Biohaven Pharmaceutical rises 70.7%
- $9.40 /
-3.5101 (-27.19%) - 05/10/22
- Bausch Health holds about 90% of Bausch + Lomb common shares after IPO
- 05/10/22
- Bausch Health falls -24.0%
- 05/10/22
- Bausch Health falls -28.9%
- 05/10/22
- Bausch Health falls -36.1%
AUPH Aurinia Pharmaceuticals - $11.27 /
+2.315 (+25.87%) - 05/10/22
- Aurinia sees FY22 revenue $115M-$135M from sales of LUPKYNIS
- 02/28/22
- Aurinia expects cash to fund current plans for at least next few years
- 12/09/21
- Aurinia Pharmaceuticals reports 'positive' results from AURORA 2 study
- 11/22/21
- Aurinia sinks with buyout speculation seen as 'past its expiration'
- $59.62 /
+16.605 (+38.61%) - 05/10/22
- Appian awarded $2.036B in damages from Pegasystems
- 04/04/22
- Appian names Mark Matheos as CFO
- 12/15/21
- Appian announces partnership with Redox
- 12/03/21
- Appian CFO Mark Lynch to retire
- 04/12/22
- Autoliv launches multi-year commitment to support UNRSF
- 02/23/22
- Autoliv to collaborate with Polestar on climate-neutral car
- 02/18/22
- Autoliv provides exterior airbag for Nuro autonomous vehicle
- 02/17/22
- Volvo committee proposes Veoneer CEO Jan Carlson as new board member
- 05/10/22
- AdaptHealth board authorizes $200M share repurchase program
- $152.08 /
+1.155 (+0.77%) - 04/29/22
- AbbVie's RINVOQ approved by FDA for treatment of active AS
- 04/29/22
- AbbVie says no plans to cut R&D investments in 2023
- 04/29/22
- AbbVie says cystic fibrosis combination drug missed study goal
- 04/29/22
- AbbVie says confident in long-term fundamentals of business
- 05/10/22
- Apple says iPod touch will be 'available while supplies last'
- 05/03/22
- Elon Musk says Apple Store like having 30% internet tax
- 05/02/22
- Roku announces availability of Apple Music on its platform
- 05/02/22
- EU charges Apple over NFC payment restrictions on iOS devices
- 05/11/22 Wedbush
- Global Blood Therapeutics added to Best Ideas List at Wedbush
- 05/05/22 Stifel
- Stifel keeps Buy rating on Arvinas, lowers price target to $82
- 05/04/22 Wells Fargo
- Pfizer price target lowered to $55 from $60 at Wells Fargo
- 05/03/22 RBC Capital
- Clinical hold being lifted a 'clear positive' for Sangamo, says RBC Capital
BHVN Biohaven Pharmaceutical - $140.00 /
+56.78 (+68.23%) - 05/02/22 Piper Sandler
- Piper sees 'outright misinformation' on Biohaven, says buy shares
- 04/22/22 Piper Sandler
- Biohaven widening lead over AbbVie in migraine, says Piper Sandler
- 03/03/22 Mizuho
- Biohaven Pharmaceutical price target raised to $154 from $144 at Mizuho
- 05/11/22 Needham
- Peloton price target lowered to $25 from $50 at Needham
- 05/11/22 BMO Capital
- Peloton price target lowered to $12 from $24 at BMO Capital
- 05/11/22 Deutsche Bank
- Peloton price target lowered to $34 from $51 at Deutsche Bank
- 05/11/22 Baird
- Peloton price target lowered to $25 from $46 at Baird
- $2,292.38 /
+31.09 (+1.37%) - 05/10/22 Piper Sandler
- Match Group suit against Google not surprising, says Piper Sandler
- 05/03/22 Cowen
- Enovix order 'perhaps' from Apple or Google, says Cowen
- 05/02/22 Rosenblatt
- Apple price target lowered to $168 from $184 at Rosenblatt
- 04/27/22 Guggenheim
- Alphabet price target lowered to $3,000 from $3,350 at Guggenheim
- $2,287.83 /
+37.4 (+1.66%) - 05/09/22 Wells Fargo
- Wells Fargo upgrades Match Group to Overweight, lowers price target to $115
- 05/09/22 Wells Fargo
- Match Group upgraded to Overweight from Equal Weight at Wells Fargo
- 05/05/22 RBC Capital
- Match Group price target lowered to $115 from $150 at RBC Capital
- 05/10/22 Truist
- Prologis made 'compelling' bid for Duke Realty, says Truist
- 04/28/22 Wells Fargo
- Prologis price target raised to $184 from $172 at Wells Fargo
- 04/25/22 Raymond James
- Prologis price target raised to $190 from $180 at Raymond James
- 04/22/22 Deutsche Bank
- Prologis price target raised to $184 from $179 at Deutsche Bank
- 03/15/22 Wells Fargo
- Duke Realty price target lowered to $59 from $64 at Wells Fargo
- 01/18/22 Truist
- Duke Realty downgraded to Hold from Buy at Truist
- 01/13/22 Mizuho
- Duke Realty price target raised to $65 from $50 at Mizuho
- 05/11/22 Credit Suisse
- SoFi Technologies price target lowered to $9.50 from $15.50 at Credit Suisse
- 05/10/22 BofA
- SoFi Technologies price target lowered to $7 from $12 at BofA
- 04/08/22 Citi
- SoFi Technologies price target lowered to $17 from $20 at Citi
- 04/07/22 BofA
- SoFi Technologies price target lowered to $12 from $14 at BofA
- $33.63 /
-43.55 (-56.43%) - 05/11/22 Atlantic Equities
- Upstart downgraded on use of balance sheet at Atlantic Equities
- 05/11/22 Atlantic Equities
- Upstart downgraded to Neutral from Overweight at Atlantic Equities
- 05/10/22 BofA
- Upstart downgraded to Neutral from Buy at BofA
- 05/10/22 Goldman Sachs
- Upstart downgraded to Neutral from Buy at Goldman Sachs
- 05/10/22 Bernstein
- Altria Group downgraded to Market Perform from Outperform at Bernstein
- 05/09/22 Jefferies
- PM buying Swedish Match would have negative read for Altria, says Jefferies
- 04/29/22 Deutsche Bank
- Altria Group price target raised to $60 from $54 at Deutsche Bank
- 04/07/22 Cowen
- Altria Group price target raised to $53 from $51 at Cowen
- 05/10/22 Deutsche Bank
- Palantir price target lowered to $11 from $15 at Deutsche Bank
- 05/10/22 Citi
- Palantir price target lowered to $7 from $10 at Citi
- 05/09/22 RBC Capital
- RBC downgrades Palantir to sell, halves target after 'disappointing' Q1
- 05/09/22 RBC Capital
- Palantir downgraded to Underperform from Sector Perform at RBC Capital
- 05/09/22 UBS
- Autoliv upgraded to Buy on attractive entry point at UBS
- 05/09/22 UBS
- Autoliv upgraded to Buy from Neutral at UBS
- 04/26/22 Deutsche Bank
- Autoliv price target lowered to $86 from $96 at Deutsche Bank
- 04/25/22 RBC Capital
- Autoliv price target lowered to $97 from $116 at RBC Capital
- $800.05 /
+12.745 (+1.62%) - 05/10/22 Berenberg
- Tesla initiated with a Hold at Berenberg
- 04/27/22 Wedbush
- Twitter transaction 'was never ideal' for Tesla investors, says Wedbush
- 04/26/22 Wedbush
- 'Soap opera' now ends with Musk owning Twitter, says Wedbush
- 04/25/22 Gordon Haskett
- Twitter bid more attractive after market selloff, says Gordon Haskett
- 05/03/22 Oppenheimer
- Citi price target lowered to $93 from $100 at Oppenheimer
- 04/06/22 Barclays
- Citi price target lowered to $67 from $73 at Barclays
- 04/05/22 Piper Sandler
- Citi price target lowered to $70 from $80 at Piper Sandler
- 03/28/22 Morgan Stanley
- Morgan Stanley says 'war changes everything,' downgrades Citi to Underweight
- $177.65 /
+4.655 (+2.69%) - 05/02/22 Morgan Stanley
- New York Times' penetration opportunity remains compelling, says Morgan Stanley
- 04/21/22 Benchmark
- Roku price target lowered to $240 from $305 at Benchmark
- 04/21/22 Citi
- Netflix price target lowered to $295 from $450 at Citi
- 04/21/22 Edward Jones
- Netflix downgraded to Hold from Buy at Edward Jones
- 05/04/22 Piper Sandler
- Teva downgraded to Underweight from Neutral at Piper Sandler
- 04/05/22 Barclays
- Teva upgraded to Overweight from Equal Weight at Barclays
- 03/25/22 Bernstein
- Teva upgraded to Outperform from Market Perform at Bernstein
- 02/18/22 Barclays
- Teva price target lowered to $11 from $13 at Barclays
- $152.08 /
+1.155 (+0.77%) - 05/06/22 Daiwa
- AbbVie downgraded to Neutral from Outperform at Daiwa
- 05/03/22 Morgan Stanley
- Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
- 05/02/22 Morgan Stanley
- AbbVie's recent weakness a buying opportunity, says Morgan Stanley
- 05/02/22 Wells Fargo
- AbbVie price target raised to $200 from $165 at Wells Fargo
- 05/11/22 JMP Securities
- Jamf Holding price target lowered to $39 from $59 at JMP Securities
- 05/04/22 Benchmark
- Cirrus Logic price target lowered to $95 from $100 at Benchmark
- 05/04/22 Benchmark
- Skyworks price target lowered to $155 from $190 at Benchmark
- 05/04/22 KeyBanc
- Cirrus Logic price target lowered to $105 from $120 at KeyBanc
- $59.62 /
+16.605 (+38.61%) - 05/11/22 Truist
- Truist cuts Pegasystems to Hold after ruling awarded $2B in damages to Appian
- 04/27/22 Goldman Sachs
- Appian initiated with a Buy at Goldman Sachs
- 04/19/22 Barclays
- Appian price target lowered to $42 from $47 at Barclays
- 02/18/22 Truist
- Appian price target lowered to $65 from $100 at Truist
- 05/11/22 Deutsche Bank
- AdaptHealth price target lowered to $22 from $28 at Deutsche Bank
- 03/08/22 RBC Capital
- AdaptHealth price target lowered to $26 from $31 at RBC Capital
- 02/25/22 Canaccord
- AdaptHealth price target lowered to $29 from $44 at Canaccord
- 02/25/22 Truist
- AdaptHealth price target lowered to $20 from $30 at Truist
- $52.35 /
-13.58 (-20.60%) - 05/11/22 Truist
- Pegasystems downgraded to Hold from Buy at Truist
- 05/04/22 Goldman Sachs
- Pegasystems initiated with a Neutral at Goldman Sachs
- 04/29/22 JMP Securities
- Pegasystems price target lowered to $100 from $155 at JMP Securities
AUPH Aurinia Pharmaceuticals - $11.27 /
+2.315 (+25.87%) - 05/05/22 Cantor Fitzgerald
- Aurinia Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- 05/04/22 H.C. Wainwright
- Aurinia Pharmaceuticals price target lowered to $30 from $33 at H.C. Wainwright
- 04/28/22 RBC Capital
- Aurinia Pharmaceuticals price target lowered to $22 from $27 at RBC Capital
- 03/01/22 RBC Capital
- Aurinia Pharmaceuticals price target lowered to $27 from $31 at RBC Capital
- 05/11/22 Canaccord
- Cronos upgraded to Hold on operational improvements at Canaccord
- 05/11/22 CIBC
- Cronos Group upgraded to Outperformer from Neutral at CIBC
- 05/11/22 Canaccord
- Cronos Group upgraded to Hold from Sell at Canaccord
- 05/09/22 Raymond James
- Cronos Group price target raised to $6 from $5 at Raymond James
- 04/20/22 BTIG
- UWM Holdings initiated with a Neutral at BTIG
- 03/03/22 Barclays
- UWM Holdings price target lowered to $5 from $7 at Barclays
- 02/23/22 UBS
- UWM Holdings downgraded to Neutral from Buy at UBS
- 02/23/22 UBS
- UWM Holdings downgraded to Neutral from Buy at UBS
- 03/16/22 Stifel
- Desktop Metal price target lowered to $6 from $11 at Stifel
- 01/10/22 Lake Street
- Desktop Metal upgraded to Hold from Sell at Lake Street
- 01/10/22 Lake Street
- Desktop Metal upgraded to Buy from Hold at Lake Street
- 11/17/21 Credit Suisse
- Desktop Metal resumed with Neutral at Credit Suisse
- 04/01/22 Barclays
- National Vision price target raised to $52 from $43 at Barclays
- 03/01/22 Citi
- National Vision price target lowered to $55 from $58 at Citi
- 01/05/22 Wells Fargo
- National Vision price target lowered to $60 from $65 at Wells Fargo
- 11/15/21 Goldman Sachs
- National Vision downgraded to Neutral from Buy at Goldman Sachs
- $9.40 /
-3.5101 (-27.19%) - 05/11/22 Cowen
- Cowen starts Bausch + Lomb at Outperform with $35 price target
- 05/11/22 BofA
- Bausch Health price target lowered to $12 from $25 at BofA
- 02/01/22 RBC Capital
- Bausch Health price target lowered to $34 from $40 at RBC Capital
- 11/03/21 JPMorgan
- Bausch Health earnings selloff a buying opportunity, says JPMorgan
- 05/11/22 JPMorgan
- Planet Fitness upgraded to Overweight on usage trends at JPMorgan
- 05/11/22 Baird
- Planet Fitness price target lowered to $92 from $108 at Baird
- 05/11/22 Piper Sandler
- Planet Fitness price target lowered to $72 from $87 at Piper Sandler
- 05/11/22 JPMorgan
- Planet Fitness upgraded to Overweight from Neutral at JPMorgan
- 05/11/22 Deutsche Bank
- GoodRx price target lowered to $10 from $20 at Deutsche Bank
- 05/11/22 Credit Suisse
- GoodRx price target lowered to $10 from $22 at Credit Suisse
- 05/10/22 Raymond James
- GoodRx downgraded to Market Perform from Outperform at Raymond James
- 05/10/22 RBC Capital
- RBC Capital cuts GoodRx to Sector Perform on reduced visibility, pulled guidance
REYN Reynolds Consumer Products - 04/13/22 Stifel
- Reynolds Consumer Products downgraded to Hold at Stifel on higher input costs
- 04/13/22 Stifel
- Reynolds Consumer Products downgraded to Hold from Buy at Stifel
- 03/30/22 JPMorgan
- Reynolds Consumer Products price target lowered to $33 from $34 at JPMorgan
- 03/29/22 Goldman Sachs
- Reynolds Consumer Products downgraded to Sell from Buy at Goldman Sachs
- 05/10/22
- UWM Holdings reports Q1 EPS 22c, consensus 7c
- 03/01/22
- UWM Holdings reports Q4 EPS 11c, consensus 14c
- $33.63 /
-43.55 (-56.43%) - 05/09/22
- Upstart sees Q2 revenue $295M-$305M, consensus $334.81M
- 05/09/22
- Upstart sees FY22 revenue $1.25B, consensus $1.4B
- 05/09/22
- Upstart reports Q1 adjusted EPS 61c, consensus 51c
- 05/09/22
- Notable companies reporting after market close
- $800.05 /
+12.745 (+1.62%) - 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 01/26/22
- Notable companies reporting after market close
- 05/03/22
- Teva backs FY22 adjusted EPS view $2.40-$2.60, consensus $2.51
- 05/03/22
- Teva reports Q1 EPS 55c, consensus 55c
- 02/09/22
- Teva sees FY22 EPS $2.40-$2.60, consensus $2.64
- 02/09/22
- Teva reports Q4 EPS 77c, consensus 73c
- 05/10/22
- SoFi Technologies sees FY22 adjusted revenue $1.505B-$1.51B, consensus $1.46B
- 05/10/22
- SoFi Technologies sees Q2 adjusted net revenue $330M-$340M, consensus $343.9M
- 05/10/22
- SoFi Technologies reports Q1 EPS (14c), consensus (14c)
- 05/10/22
- SoFi Technologies sees FY22 adjusted revenue $1.51B, Bloomberg says
REYN Reynolds Consumer Products - 05/10/22
- Reynolds Consumer Products sees Q2 EPS 23c-27c, consensus 39c
- 05/10/22
- Reynolds Consumer Products reports Q1 EPS 26c, consensus 26c
- 02/09/22
- Reynolds Consumer Products sees FY22 adjusted EPS $1.56-$1.70, consensus $1.73
- 02/09/22
- Reynolds Consumer Products sees Q1 adjusted EPS 24c-28c, consensus 30c
- 05/10/22
- Peloton sees Q4 revenue $675M-$700M, consensus $821.68M
- 05/10/22
- Peloton reports Q3 EPS ($2.27), consensus (83c)
- 05/09/22
- Notable companies reporting before tomorrow's open
- 05/09/22
- Palantir sees Q2 revenue base case $470M, consensus $483.84M
- 05/09/22
- Palantir sees annual revenue growth 30% or greater through 2025
- 05/09/22
- Palantir reports Q1 EPS 2c, consensus 4c
- 02/17/22
- Palantir sees annual revenue growth of 30% or greater through 2025
- 05/10/22
- Planet Fitness sees 2022 revenue increasing in mid-50 percent range
- 05/10/22
- Planet Fitness reports Q1 adjusted EPS 32c, consensus 27c
- 04/19/22
- Prologis raises FY22 core FFO view to $5.10-$5.16 from $5.00-$5.10
- 04/19/22
- Prologis reports Q1 core FFO $1.09, consensus $1.08
- 01/19/22
- Prologis sees 2022 core FFO $5.00-$5.10, consensus $4.63
- 01/19/22
- Prologis reports Q4 core FFO $1.12, consensus $1.10
- 05/03/22
- Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55
- 05/03/22
- Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47
- 05/02/22
- Notable companies reporting before tomorrow's open
- $52.35 /
-13.58 (-20.60%) - 04/28/22
- Pegasystems reports Q1 non-GAAP EPS 59c, consensus 26c
- 02/17/22
- Pegasystems sees FY22 EPS 75c-$1.00, consensus 84c
- 02/17/22
- Pegasystems reports Q4 EPS 4c, consensus 12c
- $177.65 /
+4.655 (+2.69%) - 04/19/22
- Netflix sees Q2 EPS $3.00, consensus $3.01
- 04/19/22
- Netflix reports Q1 EPS $3.53, consensus $2.90
- 04/19/22
- Notable companies reporting after market close
- 01/20/22
- Netflix sees Q1 EPS $2.86, consensus $3.45
- 05/03/22
- Match Group sees Q2 revenue $800M-$810M, consensus $835.2M
- 05/03/22
- Match Group reports Q1 EPS 60c, consensus 54c
- 05/03/22
- Notable companies reporting after market close
- 02/01/22
- Match Group sees FY22 revenue up 15%-20% y/y, consensus $3.62B
- 04/28/22
- Altria Group backs FY22 adjusted EPS $4.79-$4.93, consensus $4.84
- 04/28/22
- Altria Group reports Q1 adjusted EPS $1.12, consensus $1.18
- 04/27/22
- Notable companies reporting before tomorrow's open
- $2,292.38 /
+31.09 (+1.37%) - 04/26/22
- Alphabet reports Q1 EPS $24.62, consensus $25.96
- 04/26/22
- Notable companies reporting after market close
- 02/01/22
- Alphabet reports Q4 EPS $30.69, consensus $27.32
- 02/01/22
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- 05/10/22
- National Vision lowers FY22 adjusted EPS view to 65c-80c from $1.03-$1.10
- 05/10/22
- National Vision reports Q1 adjusted EPS 33c, consensus 30c
- 02/28/22
- National Vision sees 2022 adjusted EPS $1.03-$1.10, consensus $1.32
- 02/28/22
- National Vision reports Q4 adjusted EPS 13c, consensus (2c)
- 04/27/22
- Duke Realty raises FY22 core FFO view to $1.88-$1.94 from $1.87-$1.93
- 04/27/22
- Duke Realty reports Q1 core EPS 44c, consensus 44c
- 01/26/22
- Duke Realty sees FY22 core FFO $1.87-$1.93, consensus $1.89
- 01/26/22
- Duke Realty reports Q4 core FFO 44c, consensus 45c
- 05/10/22
- Desktop Metal sees 2022 revenue $260M, consensus $255.13M
- 05/10/22
- Desktop Metal reports Q1 EPS (22c), consensus (13c)
- 03/08/22
- Desktop Metal sees FY22 revenue $260M, consensus $253M
- 03/08/22
- Desktop Metal reports Q4 revenue $56.7M, consensus $49.58M
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 04/14/22
- Citi reports Q1 EPS $2.02, consensus $1.55
- 04/13/22
- Notable companies reporting before tomorrow's open
- 01/14/22
- Citi reports Q4 EPS $1.46, consensus $1.37
BHVN Biohaven Pharmaceutical - $140.00 /
+56.78 (+68.23%) - 05/10/22
- Biohaven Pharmaceutical sees 2022 net product sales $825M-$900M
- 05/10/22
- Biohaven Pharmaceutical reports Q1 EPS ($2.97), consensus ($2.53)
- 02/25/22
- Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.32), consensus ($2.04)
- $9.40 /
-3.5101 (-27.19%) - 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 05/10/22
- Bausch Health reports Q1 EPS (19c), consensus $1.29
- 02/23/22
- Bausch Health sees FY22 revenue $8.4B-8.6B, consensus $8.74B
- 02/23/22
- Bausch Health reports Q4 GAAP EPS 19c, consensus $1.11
AUPH Aurinia Pharmaceuticals - $11.27 /
+2.315 (+25.87%) - 05/10/22
- Aurinia Pharmaceuticals reports Q1 EPS (27c), consensus (27c)
- 02/28/22
- Aurinia Pharmaceuticals sees 2022 net revenue $115M-$135M
- 02/28/22
- Aurinia Pharmaceuticals reports Q4 EPS (25c) vs. (6c) last year
- $59.62 /
+16.605 (+38.61%) - 05/05/22
- Appian sees FY22 EPS (82c)-(77c), consensus (81c)
- 05/05/22
- Appian sees Q2 EPS (37c)-(33c), consensus (30c)
- 05/05/22
- Appian reports Q1 EPS (6c), consensus (13c)
- 02/17/22
- Appian sees FY22 EPS (83c) to (80c), consensus (85c)
- 04/22/22
- Autoliv reports Q1 adjusted EPS 45c, consensus $1.11
- 04/22/22
- Autoliv now sees FY22 organic sales growth of around 12%-17%
- 04/22/22
- Autoliv reports Q1 adjusted EPS 45c, consensus $1.11
- 01/28/22
- Autoliv reports Q4 adjusted EPS $1.30, consensus $1.18
- 05/10/22
- AdaptHealth sees 2022 revenue $2.84B-$3.04B, consensus $2.92B
- 05/10/22
- AdaptHealth reports Q1 EPS 8c, consensus 18c
- 02/24/22
- AdaptHealth raises FY22 revenue view to $2.825B-$3.025B from $2.7B-$2.9B
- 02/24/22
- AdaptHealth reports Q4 EPS 15c, consensus 34c
- $152.08 /
+1.155 (+0.77%) - 04/29/22
- AbbVie sees FY22 revenue $59.4B, consensus $60.22B
- 04/29/22
- AbbVie sees Q2 adjusted EPS $3.38-$3.42, consensus $3.50
- 04/29/22
- AbbVie cuts FY22 adjusted EPS view to $13.92-$14.12 from $14.00-$14.20
- 04/29/22
- AbbVie reports Q1 adjusted EPS $3.16, consensus $3.14
- 04/28/22
- Apple says y/y Q3 revenue growth to be impacted by COVID
- 04/28/22
- Apple reports Q2 EPS $1.52, consensus $1.43
- 04/28/22
- Notable companies reporting after market close
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 05/10/22
- UWM Holdings sees Q2 production in $26B-$33B range
- 03/01/22
- UWM Holdings sees Q1 production $33B-$42B
- 11/19/21
- UWM Holdings rises 18.4%
- 11/19/21
- UWM Holdings rises 24.3%
- $30.97 /
-46.21 (-59.87%) - 05/10/22
- Upstart Holdings trading resumes
- 05/10/22
- Upstart Holdings trading halted, volatility trading pause
- 05/09/22
- Upstart drops 44% to $43.30 after cutting FY22 guidance
- 04/25/22
- CFPB invokes dormant authority to examine nonbank companies
- 05/09/22
- Hindenburg shorts Twitter on risk of deal getting repriced lower
- 05/08/22
- Fly Intel: Top five weekend stock stories
- 05/06/22
- Elon Musk says hasn't had communication with Trump
- 05/06/22
- Vale confirms supply deal with Tesla for low-carbon nickel
- $12.24 /
-1.885 (-13.35%) - 05/10/22
- Peloton CEO: William Lynch to resign from board to pursue other interests
- 05/10/22
- Peloton: Recent price increases 'look promising'
- 05/10/22
- Peloton sees talent additions across organization in coming months, says CEO
- 05/10/22
- Peloton CEO: Price increase geared towards moving hardware
- 05/09/22
- Palantir falls -20.8%
- 05/09/22
- Palantir falls -21.7%
- 05/09/22
- Palantir falls -19.3%
- 04/15/22
- Palantir announces expansion to partnership with CDC
- 05/10/22
- Planet Fitness announces development agreement in New Zealand
- 01/12/22
- Planet Fitness says ended FY21 with 15.2M members
- 01/11/22
- Planet Fitness to acquire 114 locations from top franchisee, Sunshine Fitness
- 05/10/22
- Duke Realty jumps 18% to $56.53 after Prologis buyout proposal
- 05/10/22
- Prologis proposes to acquire Duke Realty in all-stock deal valued at $61.68
- 04/19/22
- Prologis CEO: We operate in 19 different countries
- 04/19/22
- Prologis reports Q1 Cash Same Store NOI 8.7%
- 05/10/22
- Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share in cash
- 05/06/22
- Myovant Sciences and Pfizer provide update on Myfembree sNDA in endometriosis
- 05/03/22
- Pfizer CEO says 'delivering on our production commitments for Paxlovid'
- $44.21 /
-21.72 (-32.94%) - 05/10/22
- Pegasystems trading resumes
- 05/10/22
- Pegasystems trading halted, volatility trading pause
- 02/17/22
- Pegasystems' President of Global Client Engagement to resign
- $174.36 /
+1.365 (+0.79%) - 04/20/22
- Pershing Square sells Netflix investment
- 04/19/22
- Netflix says will figure out advertising in next year or two
- 04/19/22
- Netflix says Q2 typically a softer quarter seasonally
- 04/19/22
- Netflix to test ways to charge for account sharing this year
- 05/09/22
- Match Group files lawsuit against Google over unlawful billing mandates
- 05/03/22
- Match Group says Shar to step down as CEO, Bernard Kim to succeed
- 05/03/22
- Match Group names Bernard Kim as CEO
- 04/04/22
- Verizon's Visible, Match Group announce partnership on Singles Registry
- 04/28/22
- FDA proposes rules prohibiting menthol cigarettes and flavored cigars
- 04/13/22
- JUUL to pay Washington $22.5M over advertising practices
- 04/11/22
- Lexaria Bioscience enters new agreements with Altria Client Services
- 03/11/22
- FDA authorizes reduced exposure claim for IQOS 3 System Holder and Charger
- $2,295.72 /
+34.43 (+1.52%) - 05/06/22
- Netlist says court grants motion for summary judgement in Google case
- 05/05/22
- Google acquires MicroLED display maker Raxium
- 05/04/22
- Google Cloud and SAP launch native integration between Workspace and S/4HANA C
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- 04/27/22
- Evofem enters agreement with GoodRx's VitaCare Prescription Services
- 01/11/22
- Sinclair announces renewals of NBC, Fox affiliation agreements
- 05/10/22
- Fox Corp. reports Q3 affiliate revenues increased 5%
- 03/31/22
- Fox News Media signs Caitlyn Jenner to contributor role
- 02/09/22
- Fox Corp. board authorizes $4B stock repurchase program
- 01/12/22
- 2021 NFL season averaged 17.1M viewers
- 05/06/22
- Jefferies Financial says Instagram account of CEO Rich Handler was hacked
- 05/05/22
- Mark Zuckerberg says reactions on WhatsApp 'start rolling out today'
- 05/03/22
- Instagram is testing a full-screen home feed
- 04/27/22
- Meta Platforms says still expects targeting, measurement headwinds from IOS 15
- 05/10/22
- National Vision Holdings trading resumes
- 05/10/22
- National Vision Holdings trading halted, volatility trading pause
- 04/11/22
- National Vision appoints Joe VanDette as CMO
- 04/11/22
- National Vision announces Joe VanDette as chief marketing officer
EBS Emergent BioSolutions - 03/11/22
- Emergent BioSolutions initiates Phase 1 study of SIAN
- 02/18/22
- FDA says added four lots of AstraZeneca COVID vaccine acceptable for export
- 02/11/22
- Emergent BioSolutions 'disappointed' in appeals ruling in Narcan case with Teva
- 01/14/22
- Emergent BioSolutions founder and executive chairman, Fuad El-Hibri, to retire
- 05/10/22
- Duke Realty rises 15.3%
- 05/10/22
- Desktop Metal announces proposed convertible senior notes offering
- 05/09/22
- Desktop Metal 'supports' Biden Adminstration's AM Forward initiative
- 05/06/22
- Biden Administration announces launch of 'Additive Manufacturing Forward' plan
- 03/08/22
- Desktop Metal rises 11.3%
- 03/21/22
- Cronos Group founder Mike Gorenstein returns as CEO
- 03/01/22
- Cronos Group announces planned exit of Peace Naturals Campus in Ontario
- 02/18/22
- Cronos Group announces strategic realignment for $20M-$25M in savings
- 02/18/22
- Cronos Group completes Audit Committee evaluation
- 05/09/22
- Citi says regulators investigating CGMI over record-keeping compliance
- 05/09/22
- Citi in talks with 'number of potential buyers' for Russia operations
- 05/04/22
- Citi raises base rate to 4.00% from 3.50%
- 04/26/22
- Citi implementing U.S. sanctions against Russia, says CEO Fraser
BHVN Biohaven Pharmaceutical - $141.55 /
+58.33 (+70.09%) - 05/10/22
- Biohaven Pharmaceutical rises 70.2%
- 05/10/22
- Biohaven Pharmaceutical rises 70.8%
- 05/10/22
- Biohaven Pharmaceutical rises 70.7%
- 05/10/22
- Pfizer to acquire Biohaven Pharmaceuticals for $148.50 per share
- 05/10/22
- Bausch Health falls -24.0%
- 05/10/22
- Bausch Health falls -28.9%
- 05/10/22
- Bausch Health falls -36.1%
- 05/06/22
- Bausch Health appoints Richard Mulligan to board of directors
AUPH Aurinia Pharmaceuticals - 05/10/22
- Aurinia sees FY22 revenue $115M-$135M from sales of LUPKYNIS
- 02/28/22
- Aurinia expects cash to fund current plans for at least next few years
- 12/09/21
- Aurinia Pharmaceuticals reports 'positive' results from AURORA 2 study
- 11/22/21
- Aurinia sinks with buyout speculation seen as 'past its expiration'
- $54.56 /
+11.55 (+26.85%) - 05/10/22
- Appian awarded $2.036B in damages from Pegasystems
- 04/04/22
- Appian names Mark Matheos as CFO
- 12/15/21
- Appian announces partnership with Redox
- 12/03/21
- Appian CFO Mark Lynch to retire
- 04/12/22
- Autoliv launches multi-year commitment to support UNRSF
- 02/23/22
- Autoliv to collaborate with Polestar on climate-neutral car
- 02/18/22
- Autoliv provides exterior airbag for Nuro autonomous vehicle
- 02/17/22
- Volvo committee proposes Veoneer CEO Jan Carlson as new board member
- 05/10/22
- AdaptHealth board authorizes $200M share repurchase program
BHVN Biohaven Pharmaceutical - $141.55 /
+58.33 (+70.09%) - 05/02/22 Piper Sandler
- Piper sees 'outright misinformation' on Biohaven, says buy shares
- 04/22/22 Piper Sandler
- Biohaven widening lead over AbbVie in migraine, says Piper Sandler
- 03/03/22 Mizuho
- Biohaven Pharmaceutical price target raised to $154 from $144 at Mizuho
- 02/25/22 Piper Sandler
- Biohaven continues execution story with two deals, says Piper Sandler
- 05/05/22 Stifel
- Stifel keeps Buy rating on Arvinas, lowers price target to $82
- 05/04/22 Wells Fargo
- Pfizer price target lowered to $55 from $60 at Wells Fargo
- 05/03/22 RBC Capital
- Clinical hold being lifted a 'clear positive' for Sangamo, says RBC Capital
- 04/20/22 Piper Sandler
- Piper says 'do not be fooled,' Arcturus Phase 3 shows strong vaccine efficacy
- $12.24 /
-1.885 (-13.35%) - 04/19/22 Citi
- Peloton assumed with Buy from Neutral at Citi
- 04/08/22 Morgan Stanley
- Peloton may top 3M Connected Fitness subscribers in Q3, says Morgan Stanley
- 03/31/22 Evercore ISI
- Peloton shares may stay range-bound in near-to-mid-term, says Evercore ISI
- 03/14/22 Bernstein
- Peloton initiated with an Outperform at Bernstein
- $30.97 /
-46.21 (-59.87%) - 05/10/22 Goldman Sachs
- Upstart downgraded to Neutral from Buy at Goldman Sachs
- 05/10/22 Wedbush
- Upstart price target lowered to $35 from $70 at Wedbush
- 05/10/22 Stephens
- Upstart downgraded to Underweight from Equal Weight at Stephens
- 05/10/22 Stephens
- Affirm downgraded to Underweight at Stephens after Upstart earnings
- 05/10/22 Piper Sandler
- Match Group suit against Google not surprising, says Piper Sandler
- 05/09/22 Wells Fargo
- Wells Fargo upgrades Match Group to Overweight, lowers price target to $115
- 05/09/22 Wells Fargo
- Match Group upgraded to Overweight from Equal Weight at Wells Fargo
- 05/05/22 RBC Capital
- Match Group price target lowered to $115 from $150 at RBC Capital
- $2,295.72 /
+34.43 (+1.52%) - 05/03/22 Cowen
- Enovix order 'perhaps' from Apple or Google, says Cowen
- 05/02/22 Rosenblatt
- Apple price target lowered to $168 from $184 at Rosenblatt
- 04/27/22 Guggenheim
- Alphabet price target lowered to $3,000 from $3,350 at Guggenheim
- $2,286.31 /
+35.88 (+1.59%) - 04/28/22 Wells Fargo
- Prologis price target raised to $184 from $172 at Wells Fargo
- 04/25/22 Raymond James
- Prologis price target raised to $190 from $180 at Raymond James
- 04/22/22 Deutsche Bank
- Prologis price target raised to $184 from $179 at Deutsche Bank
- 04/21/22 Barclays
- Prologis price target raised to $190 from $171 at Barclays
- 03/15/22 Wells Fargo
- Duke Realty price target lowered to $59 from $64 at Wells Fargo
- 01/18/22 Truist
- Duke Realty downgraded to Hold from Buy at Truist
- 01/13/22 Mizuho
- Duke Realty price target raised to $65 from $50 at Mizuho
- 01/07/22 BMO Capital
- Duke Realty downgraded to Market Perform from Outperform at BMO Capital
- 05/10/22 Bernstein
- Altria Group downgraded to Market Perform from Outperform at Bernstein
- 05/09/22 Jefferies
- PM buying Swedish Match would have negative read for Altria, says Jefferies
- 04/29/22 Deutsche Bank
- Altria Group price target raised to $60 from $54 at Deutsche Bank
- 04/07/22 Cowen
- Altria Group price target raised to $53 from $51 at Cowen
- 05/10/22 Deutsche Bank
- Palantir price target lowered to $11 from $15 at Deutsche Bank
- 05/10/22 Citi
- Palantir price target lowered to $7 from $10 at Citi
- 05/09/22 RBC Capital
- RBC downgrades Palantir to sell, halves target after 'disappointing' Q1
- 05/09/22 RBC Capital
- Palantir downgraded to Underperform from Sector Perform at RBC Capital
- 05/09/22 UBS
- Autoliv upgraded to Buy on attractive entry point at UBS
- 05/09/22 UBS
- Autoliv upgraded to Buy from Neutral at UBS
- 04/26/22 Deutsche Bank
- Autoliv price target lowered to $86 from $96 at Deutsche Bank
- 04/25/22 RBC Capital
- Autoliv price target lowered to $97 from $116 at RBC Capital
- 05/10/22 Berenberg
- Tesla initiated with a Hold at Berenberg
- 04/27/22 Wedbush
- Twitter transaction 'was never ideal' for Tesla investors, says Wedbush
- 04/26/22 Wedbush
- 'Soap opera' now ends with Musk owning Twitter, says Wedbush
- 04/25/22 Gordon Haskett
- Twitter bid more attractive after market selloff, says Gordon Haskett
EBS Emergent BioSolutions - 05/04/22 Wells Fargo
- Emergent BioSolutions price target lowered to $38 from $46 at Wells Fargo
- 04/29/22 Cantor Fitzgerald
- Emergent BioSolutions downgraded to Neutral from Overweight at Cantor Fitzgerald
- 04/29/22 Cowen
- Emergent BioSolutions price target lowered to $30 from $40 at Cowen
- 04/29/22 Chardan
- Emergent BioSolutions price target lowered to $65 from $75 at Chardan
- 05/03/22 Oppenheimer
- Citi price target lowered to $93 from $100 at Oppenheimer
- 04/06/22 Barclays
- Citi price target lowered to $67 from $73 at Barclays
- 04/05/22 Piper Sandler
- Citi price target lowered to $70 from $80 at Piper Sandler
- 03/28/22 Morgan Stanley
- Morgan Stanley says 'war changes everything,' downgrades Citi to Underweight
- $174.36 /
+1.365 (+0.79%) - 05/02/22 Morgan Stanley
- New York Times' penetration opportunity remains compelling, says Morgan Stanley
- 04/21/22 Benchmark
- Roku price target lowered to $240 from $305 at Benchmark
- 04/21/22 Citi
- Netflix price target lowered to $295 from $450 at Citi
- 04/21/22 Edward Jones
- Netflix downgraded to Hold from Buy at Edward Jones
- 04/28/22 MKM Partners
- Meta Platforms price target lowered to $295 from $315 at MKM Partners
- 04/28/22 Evercore ISI
- Meta Platforms price target lowered to $325 from $350 at Evercore ISI
- 04/28/22 Oppenheimer
- Oppenheimer maintains Outperform, $305 target on Meta Platforms after Q1 results
- 04/28/22 Credit Suisse
- Credit Suisse raises Meta Platforms price target to $273 after quarterly results
- $54.56 /
+11.55 (+26.85%) - 04/27/22 Goldman Sachs
- Appian initiated with a Buy at Goldman Sachs
- 04/19/22 Barclays
- Appian price target lowered to $42 from $47 at Barclays
- 02/18/22 Truist
- Appian price target lowered to $65 from $100 at Truist
- 01/12/22 Barclays
- Appian price target lowered to $47 from $90 at Barclays
- $44.21 /
-21.72 (-32.94%) - 05/04/22 Goldman Sachs
- Pegasystems initiated with a Neutral at Goldman Sachs
- 04/29/22 JMP Securities
- Pegasystems price target lowered to $100 from $155 at JMP Securities
- 04/19/22 Barclays
- Pegasystems price target lowered to $80 from $110 at Barclays
- 03/08/22 Truist
- Pegasystems initiated with a Buy at Truist
- 03/08/22 RBC Capital
- AdaptHealth price target lowered to $26 from $31 at RBC Capital
- 02/25/22 Canaccord
- AdaptHealth price target lowered to $29 from $44 at Canaccord
- 02/25/22 Truist
- AdaptHealth price target lowered to $20 from $30 at Truist
- 02/25/22 Deutsche Bank
- AdaptHealth price target lowered to $28 from $34 at Deutsche Bank
AUPH Aurinia Pharmaceuticals - 05/05/22 Cantor Fitzgerald
- Aurinia Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
- 05/04/22 H.C. Wainwright
- Aurinia Pharmaceuticals price target lowered to $30 from $33 at H.C. Wainwright
- 04/28/22 RBC Capital
- Aurinia Pharmaceuticals price target lowered to $22 from $27 at RBC Capital
- 03/01/22 RBC Capital
- Aurinia Pharmaceuticals price target lowered to $27 from $31 at RBC Capital
- 05/09/22 Raymond James
- Cronos Group price target raised to $6 from $5 at Raymond James
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 03/22/22 Barclays
- Cronos Group upgraded to Equal Weight from Underweight at Barclays
- 03/21/22 Stifel
- Stifel takes neutral overall view of Cronos' CEO transition
- 04/20/22 BTIG
- UWM Holdings initiated with a Neutral at BTIG
- 03/03/22 Barclays
- UWM Holdings price target lowered to $5 from $7 at Barclays
- 02/23/22 UBS
- UWM Holdings downgraded to Neutral from Buy at UBS
- 02/23/22 UBS
- UWM Holdings downgraded to Neutral from Buy at UBS
- 03/16/22 Stifel
- Desktop Metal price target lowered to $6 from $11 at Stifel
- 01/10/22 Lake Street
- Desktop Metal upgraded to Hold from Sell at Lake Street
- 01/10/22 Lake Street
- Desktop Metal upgraded to Buy from Hold at Lake Street
- 11/17/21 Credit Suisse
- Desktop Metal resumed with Neutral at Credit Suisse
- 04/01/22 Barclays
- National Vision price target raised to $52 from $43 at Barclays
- 03/01/22 Citi
- National Vision price target lowered to $55 from $58 at Citi
- 01/05/22 Wells Fargo
- National Vision price target lowered to $60 from $65 at Wells Fargo
- 11/15/21 Goldman Sachs
- National Vision downgraded to Neutral from Buy at Goldman Sachs
- 05/09/22 Evercore ISI
- Planet Fitness added to 'Tactical Outperform' list at Evercore ISI
- 04/13/22 Cowen
- Planet Fitness attractive with near-term catalysts, says Cowen
- 03/14/22 Evercore ISI
- Evercore ISI starts Planet Fitness at Outperform with $130 price target
- 03/14/22 Evercore ISI
- Planet Fitness initiated with an Outperform at Evercore ISI
- 05/10/22 Raymond James
- GoodRx downgraded to Market Perform from Outperform at Raymond James
- 05/10/22 RBC Capital
- RBC Capital cuts GoodRx to Sector Perform on reduced visibility, pulled guidance
- 05/10/22 Barclays
- GoodRx price target lowered to $15 from $28 at Barclays
- 05/10/22 SVB Leerink
- GoodRx downgraded to Market Perform from Outperform at SVB Leerink
- 02/01/22 RBC Capital
- Bausch Health price target lowered to $34 from $40 at RBC Capital
- 11/03/21 JPMorgan
- Bausch Health earnings selloff a buying opportunity, says JPMorgan
- 09/21/21 JPMorgan
- Bausch has 50% upside based on sum-of-the-parts, says JPMorgan
- 08/04/21 JPMorgan
- Bausch Health selloff on Solta IPO plans overdone, says JPMorgan
REYN Reynolds Consumer Products - 04/13/22 Stifel
- Reynolds Consumer Products downgraded to Hold at Stifel on higher input costs
- 04/13/22 Stifel
- Reynolds Consumer Products downgraded to Hold from Buy at Stifel
- 03/30/22 JPMorgan
- Reynolds Consumer Products price target lowered to $33 from $34 at JPMorgan
- 03/29/22 Goldman Sachs
- Reynolds Consumer Products downgraded to Sell from Buy at Goldman Sachs
- 04/19/22 Rosenblatt
- Fox Corp. initiated with a Neutral at Rosenblatt
- 12/14/21 Macquarie
- Fox Corp. price target lowered to $37 from $40 at Macquarie
- 08/05/21 Guggenheim
- Guggenheim upgrades Fox Corp. to Buy, maintains $41 price target
- 04/12/22 Vertical Group
- Fox Corp. upgraded to Positive from Mixed at Vertical Group
- 02/11/22 Deutsche Bank
- Fox Corp. price target raised to $48 from $47 at Deutsche Bank
- 01/24/22 UBS
- Fox Corp. upgraded to Buy from Neutral at UBS
- 05/10/22
- UWM Holdings reports Q1 EPS 22c, consensus 7c
- 03/01/22
- UWM Holdings reports Q4 EPS 11c, consensus 14c
- $30.97 /
-46.21 (-59.87%) - 05/09/22
- Upstart sees Q2 revenue $295M-$305M, consensus $334.81M
- 05/09/22
- Upstart sees FY22 revenue $1.25B, consensus $1.4B
- 05/09/22
- Upstart reports Q1 adjusted EPS 61c, consensus 51c
- 05/09/22
- Notable companies reporting after market close
- 04/20/22
- Tesla reports Q1 EPS $3.22, consensus $2.26
- 04/20/22
- Notable companies reporting after market close
- 01/26/22
- Tesla reports Q4 non-GAAP EPS $2.54, consensus $2.26
- 01/26/22
- Notable companies reporting after market close
REYN Reynolds Consumer Products - 05/10/22
- Reynolds Consumer Products sees Q2 EPS 23c-27c, consensus 39c
- 05/10/22
- Reynolds Consumer Products reports Q1 EPS 26c, consensus 26c
- 02/09/22
- Reynolds Consumer Products sees FY22 adjusted EPS $1.56-$1.70, consensus $1.73
- 02/09/22
- Reynolds Consumer Products sees Q1 adjusted EPS 24c-28c, consensus 30c
- $12.24 /
-1.885 (-13.35%) - 05/10/22
- Peloton sees Q4 revenue $675M-$700M, consensus $821.68M
- 05/10/22
- Peloton reports Q3 EPS ($2.27), consensus (83c)
- 05/09/22
- Notable companies reporting before tomorrow's open
- 05/09/22
- Palantir sees Q2 revenue base case $470M, consensus $483.84M
- 05/09/22
- Palantir sees annual revenue growth 30% or greater through 2025
- 05/09/22
- Palantir reports Q1 EPS 2c, consensus 4c
- 02/17/22
- Palantir sees annual revenue growth of 30% or greater through 2025
- 05/10/22
- Planet Fitness sees 2022 revenue increasing in mid-50 percent range
- 05/10/22
- Planet Fitness reports Q1 adjusted EPS 32c, consensus 27c
- 04/19/22
- Prologis raises FY22 core FFO view to $5.10-$5.16 from $5.00-$5.10
- 04/19/22
- Prologis reports Q1 core FFO $1.09, consensus $1.08
- 01/19/22
- Prologis sees 2022 core FFO $5.00-$5.10, consensus $4.63
- 01/19/22
- Prologis reports Q4 core FFO $1.12, consensus $1.10
- 05/03/22
- Pfizer cuts FY22 adjusted EPS view to $6.25-$6.45 from $6.35-$6.55
- 05/03/22
- Pfizer reports Q1 adjusted EPS $1.62, consensus $1.47
- 05/02/22
- Notable companies reporting before tomorrow's open
- $44.21 /
-21.72 (-32.94%) - 04/28/22
- Pegasystems reports Q1 non-GAAP EPS 59c, consensus 26c
- 02/17/22
- Pegasystems sees FY22 EPS 75c-$1.00, consensus 84c
- 02/17/22
- Pegasystems reports Q4 EPS 4c, consensus 12c
- $174.36 /
+1.365 (+0.79%) - 04/19/22
- Netflix sees Q2 EPS $3.00, consensus $3.01
- 04/19/22
- Netflix reports Q1 EPS $3.53, consensus $2.90
- 04/19/22
- Notable companies reporting after market close
- 01/20/22
- Netflix sees Q1 EPS $2.86, consensus $3.45
- 05/03/22
- Match Group sees Q2 revenue $800M-$810M, consensus $835.2M
- 05/03/22
- Match Group reports Q1 EPS 60c, consensus 54c
- 05/03/22
- Notable companies reporting after market close
- 02/01/22
- Match Group sees FY22 revenue up 15%-20% y/y, consensus $3.62B
- 04/28/22
- Altria Group backs FY22 adjusted EPS $4.79-$4.93, consensus $4.84
- 04/28/22
- Altria Group reports Q1 adjusted EPS $1.12, consensus $1.18
- 04/27/22
- Notable companies reporting before tomorrow's open
- $2,295.72 /
+34.43 (+1.52%) - 04/26/22
- Alphabet reports Q1 EPS $24.62, consensus $25.96
- 04/26/22
- Notable companies reporting after market close
- 02/01/22
- Alphabet reports Q4 EPS $30.69, consensus $27.32
- 02/01/22
- Notable companies reporting after market close
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- 05/10/22
- Fox Corp. reports Q3 adjusted EPS 81c, consensus 88c
- 02/09/22
- Fox Corp. reports Q4 adjusted EPS 13c, consensus 3c
- 04/27/22
- Meta sees Q2 revenue $28B-$30B, consensus $30.63B
- 04/27/22
- Meta Platforms reports Q1 EPS $2.72, consensus $2.56
- 04/27/22
- Notable companies reporting after market close
- 02/02/22
- Meta sees Q1 revenue $27B-29B, consensus $30.14B
- 05/10/22
- National Vision lowers FY22 adjusted EPS view to 65c-80c from $1.03-$1.10
- 05/10/22
- National Vision reports Q1 adjusted EPS 33c, consensus 30c
- 02/28/22
- National Vision sees 2022 adjusted EPS $1.03-$1.10, consensus $1.32
- 02/28/22
- National Vision reports Q4 adjusted EPS 13c, consensus (2c)
EBS Emergent BioSolutions - 04/28/22
- Emergent BioSolutions reports Q1 adjusted EPS 18c, consensus 12c
- 01/09/22
- Emergent BioSolutions sees preliminary FY21 revenue $1.78B, consensus $1.7B
- 04/27/22
- Duke Realty raises FY22 core FFO view to $1.88-$1.94 from $1.87-$1.93
- 04/27/22
- Duke Realty reports Q1 core EPS 44c, consensus 44c
- 01/26/22
- Duke Realty sees FY22 core FFO $1.87-$1.93, consensus $1.89
- 01/26/22
- Duke Realty reports Q4 core FFO 44c, consensus 45c
- 05/10/22
- Desktop Metal sees 2022 revenue $260M, consensus $255.13M
- 05/10/22
- Desktop Metal reports Q1 EPS (22c), consensus (13c)
- 03/08/22
- Desktop Metal sees FY22 revenue $260M, consensus $253M
- 03/08/22
- Desktop Metal reports Q4 revenue $56.7M, consensus $49.58M
- 05/10/22
- Cronos Group reports Q1 EPS (9c), consensus (8c)
- 03/01/22
- Cronos Group reports 2021 EPS ($1.07), consensus (47c)
- 02/18/22
- Cronos Group reports Q3 EPS 21c, consensus (10c)
- 04/14/22
- Citi reports Q1 EPS $2.02, consensus $1.55
- 04/13/22
- Notable companies reporting before tomorrow's open
- 01/14/22
- Citi reports Q4 EPS $1.46, consensus $1.37
BHVN Biohaven Pharmaceutical - $141.55 /
+58.33 (+70.09%) - 05/10/22
- Biohaven Pharmaceutical sees 2022 net product sales $825M-$900M
- 05/10/22
- Biohaven Pharmaceutical reports Q1 EPS ($2.97), consensus ($2.53)
- 02/25/22
- Biohaven Pharmaceutical reports Q4 adjusted EPS ($2.32), consensus ($2.04)
- 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 05/10/22
- Bausch Health reports Q1 EPS (19c), consensus $1.29
- 02/23/22
- Bausch Health sees FY22 revenue $8.4B-8.6B, consensus $8.74B
- 02/23/22
- Bausch Health reports Q4 GAAP EPS 19c, consensus $1.11
AUPH Aurinia Pharmaceuticals - 05/10/22
- Aurinia Pharmaceuticals reports Q1 EPS (27c), consensus (27c)
- 02/28/22
- Aurinia Pharmaceuticals sees 2022 net revenue $115M-$135M
- 02/28/22
- Aurinia Pharmaceuticals reports Q4 EPS (25c) vs. (6c) last year
- $54.56 /
+11.55 (+26.85%) - 05/05/22
- Appian sees FY22 EPS (82c)-(77c), consensus (81c)
- 05/05/22
- Appian sees Q2 EPS (37c)-(33c), consensus (30c)
- 05/05/22
- Appian reports Q1 EPS (6c), consensus (13c)
- 02/17/22
- Appian sees FY22 EPS (83c) to (80c), consensus (85c)
- 04/22/22
- Autoliv reports Q1 adjusted EPS 45c, consensus $1.11
- 04/22/22
- Autoliv now sees FY22 organic sales growth of around 12%-17%
- 04/22/22
- Autoliv reports Q1 adjusted EPS 45c, consensus $1.11
- 01/28/22
- Autoliv reports Q4 adjusted EPS $1.30, consensus $1.18
- 05/10/22
- AdaptHealth sees 2022 revenue $2.84B-$3.04B, consensus $2.92B
- 05/10/22
- AdaptHealth reports Q1 EPS 8c, consensus 18c
- 02/24/22
- AdaptHealth raises FY22 revenue view to $2.825B-$3.025B from $2.7B-$2.9B
- 02/24/22
- AdaptHealth reports Q4 EPS 15c, consensus 34c
|